TScan Therapeutics (NASDAQ:TCRX) Posts Earnings Results

TScan Therapeutics (NASDAQ:TCRX) released its quarterly earnings results on Monday. The company reported ($0.26) EPS for the quarter, topping analysts’ consensus estimates of ($0.28) by $0.02, Zacks reports. TScan Therapeutics had a negative net margin of 1,188.88% and a negative return on equity of 58.72%. The company had revenue of $2.17 million for the quarter, compared to the consensus estimate of $1.62 million.

TScan Therapeutics Stock Down 6.9%

Shares of TScan Therapeutics stock opened at $1.29 on Monday. TScan Therapeutics has a 12-month low of $1.02 and a 12-month high of $9.69. The stock’s fifty day moving average is $1.49 and its 200-day moving average is $2.69. The company has a quick ratio of 9.56, a current ratio of 9.56 and a debt-to-equity ratio of 0.13. The firm has a market capitalization of $72.72 million, a PE ratio of -1.21 and a beta of 1.06.

Analyst Upgrades and Downgrades

Several equities research analysts recently commented on the company. Barclays dropped their target price on TScan Therapeutics from $14.00 to $3.00 and set an “overweight” rating on the stock in a report on Friday, March 7th. Wedbush reissued an “outperform” rating and issued a $7.00 price objective on shares of TScan Therapeutics in a research note on Tuesday, May 6th. Needham & Company LLC reaffirmed a “buy” rating and set a $9.00 target price on shares of TScan Therapeutics in a research note on Tuesday, April 8th. HC Wainwright dropped their price target on shares of TScan Therapeutics from $15.00 to $10.00 and set a “buy” rating on the stock in a research report on Wednesday, May 7th. Finally, Morgan Stanley reiterated an “overweight” rating and issued a $10.00 price target on shares of TScan Therapeutics in a research report on Friday, March 14th. Six equities research analysts have rated the stock with a buy rating, Based on data from MarketBeat, the stock has an average rating of “Buy” and a consensus price target of $8.50.

TScan Therapeutics Company Profile

TScan Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops T cell receptor-engineered T cell (TCR-T) therapies for the treatment of patients with cancer in the United States. The company's lead product candidates include TSC-100 and TSC-101 that is in Phase I clinical trial for the treatment of patients with hematologic malignancies to eliminate residual disease and prevent relapse after allogeneic hematopoietic cell transplantation.